Herbst RS, John T, Grohe C, Goldman JW, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med 2025 Mar 17. doi: 10.1038/s41591-025-03577.
PMID: 40097663